A TAPSE/PASP ratio ≤ 0.35 was associated with higher rates of heart failure readmissions and all-cause mortality in patients undergoing MitraClip therapy (Log-Rank 8.844, p = 0.003).
Does a lower TAPSE/PASP ratio (≤ 0.35) predict increased heart failure readmissions and all-cause mortality in patients undergoing TMVR with MitraClip?
A TAPSE/PASP ratio ≤ 0.35 is a significant independent predictor of heart failure readmission and all-cause mortality in patients undergoing MitraClip implantation.
Tasa de eventos absoluta: 0% vs 0%
Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). Methods: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. Results: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. Conclusions: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection.
Trejo‐Velasco et al. (Tue,) reported a other. A TAPSE/PASP ratio ≤ 0.35 was associated with higher rates of heart failure readmissions and all-cause mortality in patients undergoing MitraClip therapy (Log-Rank 8.844, p = 0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: